Sumary of Top in hem/onc: Phase 3 data on lung cancer therapy, new leadership at Mayo Clinic:
- Results of the GEMSTONE-301 study showed that sugemalimab was well tolerated and effective in patients with stage III non-small cell lung cancer..
- Adobe Stock A randomized phase 3 study designed to evaluate sugemalimab (EQRx) as a treatment for stage III non-small cell lung cancer met its primary endpoint, according to a press release..
- For a minority patients and other historically underrepresented populations, the COVID-19 pandemic has accentuated longstanding disparities in health care..
- Aplin, PhD, has been appointed deputy director for scientific strategy at Sidney Kimmel Cancer Center — Jefferson Health….